A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
BIND Therapeutics
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Males or females at least 18 years of age
Diagnosis of NSCLC with locally advanced or metastatic disease
Positive for KRAS mutation or Squamous cell histology
Previously treated with one platinum-based chemotherapy
Disease status must be that of measurable and/or evaluable disease
Performance status of 0 to 1 on the ECOG Scale
Prior chemotherapy completed at least 3 weeks prior to study enrollment
Prior radiation therapy allowed to \< 25% of the bone marrow
Patient compliance and geographic proximity that allow adequate follow-up
Adequate organ function
Patients with reproductive potential must use contraceptive methods
Signed informed consent from patient
You may not be if
Active infection
Pregnancy or planning to become pregnant
Breast feeding
Serious concomitant systemic disorders
Second primary malignancy
Patients who are symptomatic from brain metastasis
Presence of detectable (by physical exam) third-space fluid collections
More than 1 prior cytotoxic chemotherapy regimen for advanced disease
Prior treatment with docetaxel
History of severe hypersensitivity reaction to polysorbate 80
Peripheral neuropathy at study entry
Patients known to be HIV positive
Patients known to be seropositive for hepatitis C hepatitis B
Congenital long QT syndrome, congestive heart failure, or bradyarrhythmia
Clareo Health | A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer
